Zacks Small Cap Issues Negative Forecast for ARWR Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities researchers at Zacks Small Cap cut their FY2025 earnings estimates for Arrowhead Pharmaceuticals in a research note issued to investors on Tuesday, September 2nd. Zacks Small Cap analyst D. Bautz now expects that the biotechnology company will post earnings of ($0.07) per share for the year, down from their prior estimate of $0.30. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. Zacks Small Cap also issued estimates for Arrowhead Pharmaceuticals’ Q4 2025 earnings at ($0.23) EPS, FY2026 earnings at ($0.83) EPS and FY2027 earnings at ($2.62) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to analysts’ expectations of $29.01 million. During the same quarter in the prior year, the company posted ($1.38) EPS.

Other equities research analysts have also recently issued research reports about the stock. Chardan Capital reissued a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. Royal Bank Of Canada cut their price objective on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating for the company in a research report on Friday, August 8th. TD Cowen raised shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a research report on Monday, July 28th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. Finally, Wall Street Zen cut shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $43.14.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $29.08 on Friday. The firm’s fifty day moving average price is $18.78 and its two-hundred day moving average price is $16.26. The company has a market cap of $4.02 billion, a P/E ratio of -22.72 and a beta of 1.00. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $29.34. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87.

Insider Activity

In other news, insider James C. Hamilton sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $25.00, for a total value of $375,000.00. Following the completion of the transaction, the insider owned 247,122 shares of the company’s stock, valued at $6,178,050. This represents a 5.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold a total of 25,000 shares of company stock valued at $575,000 over the last three months. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 138.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock worth $60,962,000 after buying an additional 2,774,933 shares in the last quarter. Marshall Wace LLP increased its position in shares of Arrowhead Pharmaceuticals by 3,507.8% during the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after purchasing an additional 2,096,238 shares during the last quarter. Norges Bank purchased a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $30,414,000. Vanguard Group Inc. increased its position in shares of Arrowhead Pharmaceuticals by 8.4% during the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock valued at $168,201,000 after purchasing an additional 1,018,273 shares during the last quarter. Finally, Farallon Capital Management LLC purchased a new stake in Arrowhead Pharmaceuticals in the 4th quarter worth about $11,821,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.